SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent ...

First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 Recommended Phase 2 dose and initial data from Phase 1b/2 study of lanraplenib in ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced that it has appointed Philip Gutry as its Chief Business Officer. In this newly created ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and autoimmune diseases ...

Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024. Dr Knobelman will also become principal executive and ...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and ...

The latest price target for Kronos Bio (NASDAQ:KRON) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $1.00 expecting KRON to rise to within 12 months (a ...

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial ...